Recombinant Human Angiotensin-Converting Enzyme 2 and COVID-19 Acute Respiratory Distress Syndrome: A Theoretical or a Real Resource?
- 1 January 2020
- journal article
- letter
- Published by Kare Publishing in Eurasian Journal of Medicine and Oncology
- Vol. 4 (2), 139-140
- https://doi.org/10.14744/ejmo.2020.47992
Abstract
Eurasian Journal of Medicine and OncologyKeywords
This publication has 6 references indexed in Scilit:
- Risk Factors for Mortality in 244 Older Adults With COVID-19 in Wuhan, China: A Retrospective StudyJournal of the American Geriatrics Society, 2020
- Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS CoronavirusJournal of Virology, 2020
- Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injuryScience China Life Sciences, 2020
- Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in south XinjiangHypertension Research, 2019
- A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndromeCritical Care, 2017
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005